Navigating 4 Analyst Ratings For Sutro Biopharma

Ratings for Sutro Biopharma STRO were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.75, a high estimate of $17.00, and a low estimate of $8.00. A decline of 7.26% from the prior average price target is evident in the current average.

Exploring Analyst Ratings: An In-Depth Overview

The perception of Sutro Biopharma by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sutro Biopharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sutro Biopharma compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Sutro Biopharma's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into Sutro Biopharma's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Sutro Biopharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Sutro Biopharma: A Closer Look

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Unraveling the Financial Story of Sutro Biopharma

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Decline in Revenue: Over the 3 months period, Sutro Biopharma faced challenges, resulting in a decline of approximately -32.7% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Sutro Biopharma's net margin excels beyond industry benchmarks, reaching -291.21%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Sutro Biopharma's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -36.91%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Sutro Biopharma's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.99%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Sutro Biopharma's debt-to-equity ratio is below the industry average. With a ratio of 0.34, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Core of Analyst Ratings: What Every Investor Should Know

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.